A non-inhaled treatment for severe asthma called mepolizumab resulted in fewer exacerbations among eosinophilic asthma patients and reduced daily oral corticosteroid use, according to a pair of late-stage studies released by GlaxoSmithKline Wednesday. In both studies, adverse reactions were similar for the asthma drug users and the placebo groups.

Related Summaries